Prime Medicine earnings were -$187.9M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest PRME earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$42.1M, down 14.3% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PRME reported annual earnings of -$201.1M, with 2.7% growth.
On PRME's earnings call on Aug 6, 2026, Prime Medicine (NASDAQ: PRME) reported Q2 2026 earnings per share (EPS) of -$0.24, up 41.46% year over year. Total PRME earnings for the quarter were -$42.11 million. In the same quarter last year, Prime Medicine's earnings per share (EPS) was -$0.41.
As of the last Prime Medicine earnings report, Prime Medicine is currently losing money. Prime Medicine's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$187.89 million, a 5.71% decrease year over year.
What was PRME's earnings growth in the past year?
As of Prime Medicine's earnings date in Aug 6, 2026, Prime Medicine's earnings has grown year over year. PRME earnings in the past year totalled -$187.89 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.